Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDHB | P21912 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 15/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7144668 | 0.87 | PTGS2 (0.49) | SDHBPTGS2PTGS1 | |
| SCHEMBL5597397 | 0.83 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL27731904 | 0.79 | SDHB (0.50) | SDHBPTGS2PTGS1 | |
| SCHEMBL7147045 | 0.78 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL6532907 | 0.74 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL29662867 | 0.71 | MAPK14 (0.56) | SDHBPTGS2PTGS1MAPK14 | |
| SCHEMBL7775612 | 0.71 | POLB (0.44) | SDHBPTGS2 | |
| SCHEMBL19805674 | 0.69 | SDHB (1.00) | SDHBPTGS2PTGS1 | |
| SCHEMBL8908072 | 0.68 | PTGS2 (0.56) | PTGS2PTGS1SYK | |
| SCHEMBL6448446 | 0.68 | MAPK14 (0.64) | SDHBPTGS2PTGS1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | TXNRD2, PRDX5, PTGS2 | SDHB 91/4885PTGS2 3/4885PTGS1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.